JP2004523594A - 粉末吸入製剤 - Google Patents

粉末吸入製剤 Download PDF

Info

Publication number
JP2004523594A
JP2004523594A JP2002578923A JP2002578923A JP2004523594A JP 2004523594 A JP2004523594 A JP 2004523594A JP 2002578923 A JP2002578923 A JP 2002578923A JP 2002578923 A JP2002578923 A JP 2002578923A JP 2004523594 A JP2004523594 A JP 2004523594A
Authority
JP
Japan
Prior art keywords
drug
dosage form
pharmaceutical dosage
poloxamer
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002578923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004523594A5 (enExample
Inventor
ペテルズ カロリン ベヒトルト
ハン ニュイエン
ジェフリー ロウリー
Original Assignee
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト filed Critical ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Publication of JP2004523594A publication Critical patent/JP2004523594A/ja
Publication of JP2004523594A5 publication Critical patent/JP2004523594A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002578923A 2001-03-21 2002-03-16 粉末吸入製剤 Pending JP2004523594A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0107106.7A GB0107106D0 (en) 2001-03-21 2001-03-21 Powder inhaler formulations
PCT/EP2002/002948 WO2002080884A2 (en) 2001-03-21 2002-03-16 Powder inhaler formulations

Publications (2)

Publication Number Publication Date
JP2004523594A true JP2004523594A (ja) 2004-08-05
JP2004523594A5 JP2004523594A5 (enExample) 2009-07-23

Family

ID=9911273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002578923A Pending JP2004523594A (ja) 2001-03-21 2002-03-16 粉末吸入製剤

Country Status (10)

Country Link
US (3) US20030007932A1 (enExample)
EP (1) EP1372610B1 (enExample)
JP (1) JP2004523594A (enExample)
AT (1) ATE556704T1 (enExample)
AU (1) AU2002316820A1 (enExample)
CA (1) CA2440010C (enExample)
GB (1) GB0107106D0 (enExample)
MX (1) MXPA03008398A (enExample)
UY (1) UY27218A1 (enExample)
WO (1) WO2002080884A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006151980A (ja) * 2004-11-30 2006-06-15 Basf Ag 微造粒ポリマーの形成方法
JP2011502102A (ja) * 2006-11-22 2011-01-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬を含有する安定な粉末製剤
JP2015517351A (ja) * 2012-05-14 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤入りブリスタを収容する器具
JP2020531417A (ja) * 2017-08-20 2020-11-05 フォーミュレックス ファーマ イノベーションズ リミテッド 鼻腔内送達用乾燥粉末組成物
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN102688224A (zh) * 2003-04-14 2012-09-26 维克特拉有限公司 用于提高剂量效率的药物组合物和装置
SE0302665D0 (sv) 2003-10-07 2003-10-07 Astrazeneca Ab Novel Process
ITMI20040795A1 (it) * 2004-04-23 2004-07-23 Eratech S R L Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
EP3199164B1 (en) 2005-02-10 2020-03-18 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
DK1917253T3 (da) 2005-08-15 2015-03-30 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af betamimetika
JP2010534248A (ja) 2007-07-21 2010-11-04 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ピリジノン置換インダゾール
CN103351390A (zh) 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
EP2476680B1 (en) 2008-01-11 2014-08-27 Albany Molecular Research, Inc. (1-Azinone)-Substituted Pyridoindoles
EP2349224B1 (en) 2008-10-10 2017-05-10 Probelte Pharma, S.A. Orally administrable immunostimulant product for aquaculture
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US8673931B2 (en) 2009-01-26 2014-03-18 Abraham Fisher Bicyclic heterocyclic spiro compounds
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
EP3130396B1 (en) 2009-03-27 2021-03-17 Bend Research, Inc. Spray-drying process
TR200909788A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
EP2611530B1 (en) 2010-09-03 2019-01-16 Bend Research, Inc. Spray-drying apparatus and methods of using the same
EP2618924A1 (en) 2010-09-24 2013-07-31 Bend Research, Inc. High-temperature spray drying process and apparatus
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
US10105500B2 (en) 2012-05-09 2018-10-23 Virginia Commonwealth University Dry powder inhaler (DPI) designs for producing aerosols with high fine particle fractions
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) * 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
PT3212169T (pt) 2014-10-31 2021-05-06 Bend Res Inc Processo para formar domínios ativos dispersos numa matriz
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
US11786460B2 (en) * 2018-04-16 2023-10-17 Ioulia Tseti Pharmaceutical dry powder composition for inhalation comprising a thyroid hormone
US10966943B2 (en) 2018-09-06 2021-04-06 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
EP3906233B1 (en) 2018-12-31 2024-01-31 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999016419A1 (en) * 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Perforated microparticles and methods of use
WO2000027363A1 (en) * 1998-11-12 2000-05-18 Elan Pharma International Ltd. Aerosols comprising nanoparticle drugs
WO2000028979A1 (de) * 1998-11-13 2000-05-25 Jago Research Ag Trockenpulver zur inhalation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL263733A (enExample) * 1960-04-19 1900-01-01
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4533542A (en) * 1983-08-22 1985-08-06 Eli Lilly And Company Pharmaceutical compositions for storage in plastic containers and process therefor
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9026025D0 (en) * 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6645644B1 (en) * 1996-10-17 2003-11-11 The Trustees Of Princeton University Enhanced bonding of phosphoric and phosphoric acids to oxidized substrates
US5874111A (en) * 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999016419A1 (en) * 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Perforated microparticles and methods of use
WO2000027363A1 (en) * 1998-11-12 2000-05-18 Elan Pharma International Ltd. Aerosols comprising nanoparticle drugs
WO2000028979A1 (de) * 1998-11-13 2000-05-25 Jago Research Ag Trockenpulver zur inhalation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5003015391, ＥＵＲＯＰＥＡＮ ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ ＳＣＩＥＮＣＥＳ, 1996, Ｖｏｌ． ４， Ｎｏ． ＳＵＰＰＬ．, ｐ． Ｓ６５ *
JPN5003015392, ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＹ ＡＮＤ ＰＨＡＲＭＡＣＯＬＯＧＹ, 1997, Ｖｏｌ． ４９， Ｎｏ． ＳＵＰＰＬ．４, ｐ． ４１ *
JPN5003015393, ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＥＵＴＩＣＳ, 19990525, Ｖｏｌ． １８２， Ｎｏ． ２, ｐ． １９９−２１１ *
JPN5003015396, ＥＵＲＯＰＥＡＮ ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ ＳＣＩＥＮＣＥＳ, 199808, Ｖｏｌ． ６， Ｎｏ． ＳＵＰＰＬ． １, ｐ． Ｓ６３ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006151980A (ja) * 2004-11-30 2006-06-15 Basf Ag 微造粒ポリマーの形成方法
JP2011502102A (ja) * 2006-11-22 2011-01-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬を含有する安定な粉末製剤
JP2015517351A (ja) * 2012-05-14 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤入りブリスタを収容する器具
JP2020531417A (ja) * 2017-08-20 2020-11-05 フォーミュレックス ファーマ イノベーションズ リミテッド 鼻腔内送達用乾燥粉末組成物
JP7334145B2 (ja) 2017-08-20 2023-08-28 ネイサス ファーマ リミテッド 鼻腔内送達用乾燥粉末組成物
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery

Also Published As

Publication number Publication date
US20080057003A1 (en) 2008-03-06
EP1372610B1 (en) 2012-05-09
CA2440010A1 (en) 2002-10-17
US20030007932A1 (en) 2003-01-09
ATE556704T1 (de) 2012-05-15
EP1372610A2 (en) 2004-01-02
WO2002080884A2 (en) 2002-10-17
CA2440010C (en) 2012-07-10
GB0107106D0 (en) 2001-05-09
UY27218A1 (es) 2002-10-31
AU2002316820A1 (en) 2002-10-21
MXPA03008398A (es) 2004-01-29
US20050196346A1 (en) 2005-09-08
WO2002080884A3 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
JP2004523594A (ja) 粉末吸入製剤
JP5622730B2 (ja) チオトロピウム含有吸入可能粒子
SK284775B6 (sk) Častice aminokyseliny, spôsob ich prípravy, prášok s ich obsahom, spôsob jeho prípravy, inhalátor s jeho obsahom a ich použitie
PL204251B1 (pl) Proszek do zastosowania w inhalatorze na suchy proszek oraz sposoby wykonania tego proszku
EP3377108B1 (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
NZ504711A (en) Soft-pellet drug and process for the preparation thereof
JPWO1994008709A1 (ja) 微細な造粒体の製造方法
CZ20021785A3 (cs) Inhalační prášek obsahující tiotropium
CN100560067C (zh) 盐酸决奈达隆口服药物组合物及其制备方法
CN103052379A (zh) 包含磷酸二酯酶抑制剂的干粉制剂
JP2002524535A (ja) 乾燥粉末活性薬剤肺性送達
KR102462058B1 (ko) 제제의 안정성을 증가시키기 위해 분무 건조에 의해 수득된 1종 이상의 건조 분말을 포함하는 조성물
US20120294935A1 (en) Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
SK95899A3 (en) New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
EP0964675B1 (en) Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
CN116687887A (zh) 用于吸入的干粉制剂
EP3030224B1 (en) Inhalable particles comprising tiotropium and indacaterol
US20250387327A1 (en) Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation
WO2025174856A1 (en) Process for making a composition for pulmonary inhalation
JP2025064909A (ja) 吸入用粉末剤
HK1101346B (en) Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
HK1101346A1 (en) Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
JPWO1999027911A1 (ja) 軟質ペレット状薬剤およびその製造方法
JP2012524817A (ja) 標的粒子サイズを有する、活性医薬を含む凝集体配合物
JPWO2001056581A1 (ja) 吸入用粉末製剤及びそれを充填してなる粉末吸入剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090302

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090309

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100617